A safety evaluation of current medications for adult women with the polycystic ovarian syndrome not pursuing pregnancy.

Autor:	Luque-Ramírez M; Diabetes, Obesity, and Human Reproduction Research Group, Instituto Ramón Y Cajal De Investigación Sanitaria, Centro De Investigación Biomédica En Red Diabetes Y Enfermedades Metabólicas Asociadas (CIBERDEM) & University of Alcalá , Madrid, Spain.; Department of Endocrinology and Nutrition, Hospital Universitario Ramón Y Cajal , Madrid, Spain., Ortiz-Flores AE; Diabetes, Obesity, and Human Reproduction Research Group, Instituto Ramón Y Cajal De Investigación Sanitaria, Centro De Investigación Biomédica En Red Diabetes Y Enfermedades Metabólicas Asociadas (CIBERDEM) & University of Alcalá , Madrid, Spain., Nattero-Chávez L; Diabetes, Obesity, and Human Reproduction Research Group, Instituto Ramón Y Cajal De Investigación Sanitaria, Centro De Investigación Biomédica En Red Diabetes Y Enfermedades Metabólicas Asociadas (CIBERDEM) & University of Alcalá , Madrid, Spain.; Department of Endocrinology and Nutrition, Hospital Universitario Ramón Y Cajal , Madrid, Spain., Escobar-Morreale HF; Diabetes, Obesity, and Human Reproduction Research Group, Instituto Ramón Y Cajal De Investigación Sanitaria, Centro De Investigación Biomédica En Red Diabetes Y Enfermedades Metabólicas Asociadas (CIBERDEM) & University of Alcalá , Madrid, Spain.; Department of Endocrinology and Nutrition, Hospital Universitario Ramón Y Cajal , Madrid, Spain.
Jazyk:	angličtina
Zdroj:	Expert opinion on drug safety [Expert Opin Drug Saf] 2020 Dec; Vol. 19 (12), pp. 1559-1576. Date of Electronic Publication: 2020 Nov 05.
DOI:	10.1080/14740338.2020.1839409
Abstrakt:	Introduction: The polycystic ovary syndrome (PCOS) is a very prevalent disorder in premenopausal women. Cardiovascular risk factors cluster in these patients, raising concern about the safety of the drugs commonly used to ameliorate symptoms of androgen excess in in this population at risk of cardiovascular morbidity. Areas Covered: This review summarizes the clinical efficacy and safety profiles of drugs commonly used for the management of hyperandrogenic symptoms and endometrial protection in adult women with PCOS who do not seek pregnancy. Expert Opinion: Antiandrogenic drugs usually used in adult women with PCOS carry a low risk of severe side effects. In spite of the cardiovascular risk profile of women with PCOS, and that individualized risk assessment is of paramount importance, there is no solid evidence supporting that the use of combined oral contraceptives in these women increases the risk of cardiovascular or thromboembolic events compared with the general population. However, virtually all these drugs are used in an off-label fashion. Large, high-quality studies addressing the long-term safety of pharmacological treatments in women with PCOS are definitely needed.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu